For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

PR17 (ENZAMET) featured in ASCO's Clinical Cancer Advances 2020

PR17 (ENZAMET) featured in ASCO's Clinical Cancer Advances 2020

ENZAMET | CCTG PR17 (NCT02446405) study has been highlighted by the American Society of Clinical Oncology (ASCO) 2020 annual report as a major advance in cancer treatment. The results were first presented at ASCO 2019, the trial demonstrated that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone‐sensitive prostate cancer.

More >>
 
An interview with Senior Investigator Annette Hay

An interview with Senior Investigator Annette Hay

Prof Annette Hay speaks to ecancer at the ASH 2019 meeting in Orlando about accrual barriers and detection of early toxicity signal in older, less-fit patients treated with azacitidine and nivolumab for newly diagnosed acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Prof Hay says that AML and MDS are typically diseases of older people, yet these patients are poorly represented in clinical trials.

More >>
 
Complementary Medications and outcomes in CCTG trials.

Palliative and supportive care presentation at ESMO 2019

Approximately a fifth of patients participating in phase III breast, lung, or colorectal cancer clinical trials conducted by CCTG also used complementary medicines.

More >>
 

Cell Therapy’s Promise for Canadians Must Include Access

An emerging form of immunotherapy, called adoptive cell transfer, has the potential to transform the way in which cancers are treated.

More >>
 

Planned trials

HD11

Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma

HDC1

Nivolumab or Brentuximab Vedotin plus AVD in Pts (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

More >>

MA40

Fulvestrant and Ipatasertib for Advanced/Metastatic HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER)

OV26

Maintenance Therapy with Olaparib and Cediranib or Olaparib Alone in Relapsed Platinum-sensitive Ovarian Cancer Following a Response to Platinum-Based Chemotherapy

More >>

PAC3

Perioperative vs Adjuvant Chemotherapy for Resectable Pancreatic Cancer

PR22

Darolutamide Augments Standard Therapy for Localized High-Risk Prostate Cancer (DASL-HiCaP)

More >>

Recently activated

BL13F

A Prospective Feasibility Sub-Study of BL13 - [e-PRISM]

More >>

BRC8

MRI Surveillance with or without Prophylactic Cranial Irradiation in SCLC

More >>

CEC7

Post-Surgical (SRS) Compared with (FSRS) for Resected Metastatic Brain Disease

More >>

CRC9

Circulating tumOr DNA as a Predictive BiomarRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)

More >>

CX6

International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer SENTICOL III

More >>

I234G

Carboplatin in Metastatic Castration-Resistant Prostate Cancer

More >>

IC8

COV-IMMUNO - Immunization with IMM-101 vs Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure

More >>

ICC1

NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study

More >>

ME15

1cm vs 2cm Wide Excision Margins for Primary Cutaneous Melanoma (MelMarT-II)

More >>

PM1S

Genomic Analysis in Cancer Patients: A Pan-Canadian Survey of Oncologists and Patients

More >>

SC27

Impact of COVID-19 Pandemic on Cancer Patients During Treatment and Survivors

More >>

CCTG SC.27 – Pan-Canadian Study to Examine the Impact of the COVID-19 Pandemic on Canadians Living with Cancer

How has living through the COVID-19 pandemic as a person diagnosed with cancer affected you? How are you coping? What kinds of precautions have you been taking? How has it impacted your cancer care? WE WANT TO KNOW!! The Canadian Cancer Trials Group (CCTG) has launched a patient-centred observational study called: CCTG SC.27: Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.

While the COVID-19 pandemic continues to have an unprecedented global impact, the health risks, burdens and outcomes are not the same for everyone. Cancer patients and survivors are one example of a vulnerable populatio where the impact of the pandemic deserves greater attention.

If you are an adult diagnosed with cancer within the last 10 years and are interested in reading more about the study and the opportunity to participate, please follow this link.

Covid19LivingwithCancer.ca

More >>
 
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 
TAILORx / MAC.12 breast cancer trial showed no benefit from chemotherapy for 70% of women with the most common form of breast cancer.

TAILORx | MAC12 trial showed no benefit from chemotherapy for many women with breast cancer

Clinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment.

More >>
 

Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide

Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.

More >>
 

Publications

Clinical trials navigator: Patient-centered access to clinical trials.

J Clin Oncol 38, 2020
Hamm CM;Naccarato K;Sundquist S;Kovacevic S;El-Abed Y;Dancey J;

More >>

Role of the total mutation burden (TMB) and tumor-infiltrating lymphocytes (TILs) on the development of second primary cancer after complete resection of non-small cell lung cancer (NSCLC).

J Clin Oncol 38, 2020
Gauthier M;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria J;Kratzke RA;Graziano SL;Govindan R;Tsao M;Shepherd FA;

More >>

Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer (NSCLC) patients.

J Clin Oncol 38, 2020
Fung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le Chevalier T;Soria J;Kratzke RA;Graziano SL;Devarakonda S;Govindan R;Tsao M;Shepherd FA;

More >>

The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL).

J Clin Oncol 38, 2020
Parsons SK;Rodday AM;Scharman C;Andre M;Federico M;Friedberg JW;Friedman DL;Gallamini A;Hay AE;Hoskin P;Johnson P;Kahl BS;Keller FG;Kelly KM;Meyer RM;Radford JA;Raemaekers J;Zinzani PL;Cohen JT;Evens AM;

More >>

A cost-utility analysis of apalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

J Clin Oncol 38, 2020
Parmar A;Timilshina N;Emmenegger U;Alibhai SMH;Smoragiewicz M;Sander B;Chan KK;

More >>

PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).

J Clin Oncol 38, 2020
Hass NB;Puligandla M;Allaf ME;McDermott DF;Drake CG;Signoretti S;Cella D;Gupta RT;Shuch BM;Lara P;Kapoor A;Heng DYC;Leibovich BC;Michaelson MD;Choueiri TK;Jewett MAS;Maskens D;Harshman LC;Master VA;Carducci MA;

More >>

Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care (HoLISTIC).

J Clin Oncol 38, 2020
Parsons SK;Bhakta N;Rodday AM;Scharman C;Andre M;Federico M;Friedberg JW;Friedman DL;Gallamini A;Hay AE;Kahl BS;Keller FG;Kelly KM;Meyer RM;Raemaekers J;Robison LL;Hudson MM;Cohen JT;Evens AM;Wong FL;

More >>

Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) randomized clinical trial.

J Clin Oncol 38, 2020
Song AJ;Ding K;Laperriere N;Perry JR;Mason WP;Winch C;O'Callaghan CJ;Menten J;Brandes AA;Phillips C;Fay MF;Nishikawa R;Osoba D;Cairncross G;Roa W;Wick W;Shi W;

More >>